



**2018**

**28-30 JUNE**  
**VIENNA, AUSTRIA**

**SUPPORTIVE CARE**  
**MAKES EXCELLENT**  
**CANCER CARE POSSIBLE**



**MASCC**  
**ANNUAL MEETING**



# CHARACTERISTICS OF OSTEONECROSIS OF THE JAW (MRONJ) IN CANCER PATIENTS RECEIVING ANTIRESORPTIVE AND/OR TARGETED AGENTS

**E. Papadopoulou<sup>1</sup>, O. Nicolatou-Galitis<sup>1</sup>, M. Kouri <sup>1</sup>, E. Vardas<sup>1</sup>, M. Demiri<sup>2</sup>, D. Tryfonopoulos<sup>2</sup>, MC Kyrtsonis<sup>3</sup>, A. Megalakaki<sup>4</sup>, P. Repousis<sup>4</sup>, F. Antoniou<sup>5</sup>, A. Ntokou<sup>2</sup>, M. Dede<sup>2</sup>, A. Ardavanis<sup>2</sup>**

*<sup>1</sup>Clinic of Hospital Dentistry, School of Dentistry, University of Athens, Athens, Greece*

*<sup>2</sup>1<sup>st</sup> Pathology/Oncology Department, 'Agios Savvas' Hospital, Athens, Greece*

*<sup>3</sup>'Laiko' Hospital, 1st Department of Propaedeutic Clinic of Internal Medicine, Medical School, University of Athens*

*<sup>4</sup>Metaxa Cancer Hospital, Clinic of Hematology, Piraeus, Greece*

*<sup>5</sup>Oncology Department, 'Helena Venizelou' Hospital, Athens, Greece*

[www.mascc.org/meeting](http://www.mascc.org/meeting)



#MASCC18





# INTRODUCTION & OBJECTIVES



## ∞ Introduction

∞ MRONJ is an uncommon complication associated with antiresorptives and/or targeted agents

## ∞ Objectives

∞ To present the characteristics of MRONJ based on the experience of our Clinic

➤ 2015 to 2017

# METHODS



- ❧ 243 cancer patients receiving antiresorptives and/or targeted agents were evaluated during 2015-2017
- ❧ **ONJ Group:**
  - ❧ 76 patients presented with established MRONJ
- ❧ **Prevention Group:**
  - ❧ 167 patients were referred for oral examination before/after the initiation of antiresorptives/ targeted agents

- In all patients were performed*
- ❧ Oral/ dental examination
  - ❧ Radiographic evaluation
  - ❧ Completion of medical history
  - ❧ Record of patients' habits
  - ❧ Education on oral hygiene
    - ❧ Brushing of the teeth with soft toothbrush 3 times daily
    - ❧ Use of interdental brushes
    - ❧ Daily use of antiseptic mouthwash and/or chlorhexidine gel
  - ❧ Cessation of smoking

# PATIENT DEMOGRAPHICS



## GENDER

Male: 83

Female: 160

## AGE


Mean age: 63.9 yrs

Range: 26-87 yrs

## MEDICATION



## DIAGNOSIS




# RESULTS-ONJ GROUP

ONJ was related to antiresorptives in 57 cases (75%), to antiresorptives and targeted agents in 18 (23.7%) and to targeted agents alone in one (1.3%)



## ANTIRESORPTIVES



## TARGETED AGENTS




- Mean time of administration of antiresorptives until ONJ:
  - Antiresorptives alone: 33 months
  - Combination with targeted agents: 27.8 months
- Mean time of administration of targeted agents: 15.6 months


# RESULTS-ONJ GROUP



## LOCATION OF ONJ



## RISK FACTOR



## CLINICAL PRESENTATION

- exposed bone: 54/76 (71.1%)
- non-exposed bone: 22/76 (28.9%)


Painful, mobile tooth was the reason for extraction in 21/29 patients (27.6%)

# RESULTS-ONJ GROUP

## TREATMENT

- patients were treated conservatively with long-term antibiotics, continuous or with treatment free intervals
- miconazole was used topically
- oral hygiene measures
- local ozone oil applications
- regular re-evaluations

## CLINICAL COURSE



- **Healing:** complete mucosal coverage
- **Stability:** stage I, with no signs of infection or expansion
- **Partial remission:** patients are asymptomatic, with minor mucosal inflammation
- **Progression:** patients progressed to stage III or a new site of ONJ was revealed



# RESULTS- PREVENTION GROUP



- œ Patients were referred
  - œ Prior to initiation of medication
    - œ 28/167 (16.8%)
  - œ After the initiation of medication
    - œ 139/167 (83.2%)
- œ Dental extractions were performed in 19 patients receiving medications
  - œ 13/19 (68.4%) due to pain and/or tooth mobility
  - œ All healed



**THANK YOU FOR YOUR ATTENTION**